RT Journal Article
SR Electronic
T1 The effect of neoadjuvant therapy on PD-L1 expression and CD8 lymphocyte density in non-small cell lung cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.11.22273684
DO 10.1101/2022.04.11.22273684
A1 Zens, Philipp
A1 Bello, Corina
A1 Scherz, Amina
A1 Gunten, Michael von
A1 Ochsenbein, Adrian
A1 Schmid, Ralph A
A1 Berezowska, Sabina
YR 2022
UL http://medrxiv.org/content/early/2022/04/17/2022.04.11.22273684.abstract
AB PD-L1 expression is the routine clinical biomarker for the selection of patients to receive immunotherapy in non-small cell lung cancer (NSCLC). However, the application and best timing of immunotherapy in the resectable setting is still under investigation. We aimed to study the effect of chemotherapy on PD-L1 expression and tumor infiltrating lymphocytes (TIL), which is to date still poorly understood. This retrospective, single-centre study cohort comprised 96 consecutive patients with NSCLC resected in 2000-2016 after neoadjuvant therapy, including paired chemo-naïve specimens in 57 cases. A biologically matched control cohort of 114 primary resected cases was included. PD-L1 expression, CD8+ TIL density and tertiary lymphoid structures were assessed on whole slides and correlated with clinico-pathological characteristics and survival.Seven/57 and 12/57 cases had lower respectively higher PD-L1 expressions after neoadjuvant therapy. Most cases (n = 38) had no changes in PD-L1 expression and the majority of these showed PD-L1 < 1% in both samples (23/38 [60.5%]). CD8+ TILs density was significantly higher after chemotherapy (p = 0.031) in paired resections. Neoadjuvant cases showed no difference in PD-L1 expression or CD8+ TILs density compared to the chemotherapy naïve control cohort. In univariable analyses, higher CD8+ TILs density, higher numbers of tertiary lymphoid structures but not PD-L1 expression were significantly associated with better survival. Increased PD-L1 expression after neoadjuvant chemotherapy was visually associated with worse 5-year survival, lacking statistical significance probably due to the low number of cases. PD-L1 expression is mostly unchanged after neoadjuvant chemotherapy. However, an increase of PD-L1 expression after neoadjuvant therapy could be associated with worse survival.Competing Interest StatementSB has served as compensated consultant for Basilea, Eli Lilly, MSD and Roche (payment to institution) and has received research funding from Roche outside of the current project. The other authors declare no conflict of interest.Funding StatementThe study was supported by grants from the Stiftung zur Krebsbekaempfung (SKB425) and Cancer Research Switzerland (KFS-4694-02-2019) to SB. PZ is supported by a MD-PhD scholarship of Cancer Research Switzerland (MD-PhD-5088-06-2020). The funding agencies had no role in study design, in the collection, analysis and interpretation of data, in the writing of the report or in the decision to submit the article for publication. Open Access funding provided by the University of Lausanne.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the Canton of Bern gave approval for this work (KEK 2017-00830).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized detailed clinico-pathological data and the R-Script used for data analysis are available upon request to the authors.